Skin Fluorescent Imaging (SFI) System in Patients With Nevi

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-10

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optical Frequency Domain Imaging (OFDI) in Dermatology

NCT01438047

Port Wine Stain

WITHDRAWN

Longitudinal Spatial Frequency Domain Imaging Study

NCT05672992

Systemic Scleroderma

ACTIVE_NOT_RECRUITING NA

Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure

NCT06976073

Diabetes Mellitus, Type 2 Diabetic Foot Peripheral Arterial Disease +2 more

RECRUITING

Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma

NCT02002897

Localized Scleroderma

UNKNOWN NA

Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions

NCT05927272

Vitiligo

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SFI system, a non-invasive point-of-care imaging system, is able to detect markers associated with tissue remodeling and thus provide real-time information about biological and structural changes occurring in nevi indicative of dysplastic transition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nevus Dysplasia; Epithelial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nevi undergoing biopsy per SOC

Subjects with Nevi who will as part of their standard of care, will undergo biopsy.

Skin Fluorescent Imaging

Intervention Type DIAGNOSTIC_TEST

Application of reagents, then imaging and scoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin Fluorescent Imaging

Application of reagents, then imaging and scoring

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SFI 003 Imaging

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study a subject must meet all of the following criteria:

* Provide a signed and dated informed consent form
* Age ≥ 18 years old
* Subjects must present with suspicious atypical nevi scheduled for a biopsy\*
* Nevi with at least 1 cm of skin surrounding the mole
* Nevi must be accessible to the SFI imaging device
* Excisional or a tangential excision with a dept of 1 to 2 mm biopsy will be performed for the mole tested within 21 days of testing.
* Nevi with clinically atypical features

Only 1 mole per eligible subject will be SFI tested in this study. \*NOTE: a subset of patients (\~10%) with benign nevi (by clinical observation) who wish to have nevi removed for cosmetic reasons will be enrolled as negative controls.

* Less than 1 cm from the eyes
* On the palms of the hands or soles of the feet
* Associated with scar tissue
* Mucosal lesions
* Ulcerated lesions / breached skin
* Lesions with some clinical certainty of being melanomas (large, dark, etc.)
* Any nevi with ink marking including tattoos, on or adjacent to the nevi
* Lesions treated with local anesthesia such as lidocaine prior to enrollment
* Lesions larger than 20 mm or too large to allow imaging
* Subject is known to be pregnant
* Subject who is mentally or physically unable to comply with all aspects of the study
* Subject who is undergoing systemic cancer treatment within 6 months of SFI testing
* Subject with hypersensitivity to any of the SFI reagents
* Subjects with known sensitivity to fluorescent dyes
* Any subject who has previously participated (testing to biopsy) in SFI 003

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

* Subjects who are younger than 18 years old
* Lesions that are consistent with

\- Features of Keratosis and keratin plugs
* Basal Cell Carcinoma
* Squamous Cell Carcinoma
* Challenging anatomical location (e.g., body cervices)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No